Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
APYX.US
id: 149, Created by Stan Vick Chase, Scout
Apyx Medical Inc
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
Apyx announced on March 14, 2022, that it has been notified by the FDA that the Agency intends to post a Medical Device Safety Communication related to the Company’s Advanced Energy products.
“Based on our initial interactions with the FDA, we believe the Agency’s MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures,” said Charlie Goodwin, President and CEO.
Goodwin added: “While we are aware that some of our products are being used by physicians for dermal resurfacing procedures, for which our products do not have a cleared indication, we do not and will not promote the use of our products..."
On this news, the Company’s stock fell by 40.6%, to close at $5.88 per share on March 14, 2022.
Taking into account all the facts and statements of the Company's management, there is reason to believe that they have not properly, timely and in full disclosed that a significant number of Apyx’s Advanced Energy products were used for off-label indications and such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events. As a result, the Company was reasonably likely to incur regulatory scrutiny which in turn most probably would hurt Company's business and financials.
Alleged Offence
Mismanagement,
Misleading Statements,
Financial Misrepresentation,
Failure to Disclose,
Negligence,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
14 March 2022
Court
Middle District of Florida